Table 3.

Volume therapy, transfusion requirements and need for factor concentrate administration

	Placebo (n = 25)	FC (n = 28)	Estimated difference or odds ratio (95% CI)	P
Until arrival to the Emergency department
Crystalloids
Patients	23/25 (92.0%)	26/28 (92.9%)	1.13 (0.08 to 16.72)	1
Volume (ml)	1000 [500 to 1125]	500 [500 to 1000]	0 (0 to 500)	0.8218
Colloids
Patients	15/25 (60.0%)	10/28 (35.7%)	0.38 (0.11 to 1.29)	0.1017
Volume (ml)	500 [500 to 575]	750 [500 to 1000]	0 (−500 to 0)	0.1689
Until 24 h after accident
Crystalloidsa
Volume (ml)	3100 [1500 to 5126]	3120 [937.5 to 4905.75]	199.24 (−1309 to 1692)	0.7276
Colloids
Patients	19/25 (76.0%)	16/28 (57.1%)	0.43 (0.11 to 1.58)	0.245
Volume (ml)	1000 [575 to 2500]	2475 [2000 to 5374.5]	−1385.6 (−2850 to 0)	0.041
Red blood concentrate
Patients	13/25 (52.0%)	11/28 (39.3%)	0.6 (0.17 to 2.03)	0.4145
Dose (U)	3 [3 to 6]	7 [4 to 9.5]	−2 (−5 to 1)	0.2188
Massive transfusionb	2/25 (8.0%)	3/28 (10.7%)	1.37 (0.14 to 17.80)	1
Platelet concentrate
Patients	0/25 (0.0%)	3/28 (10.7%)	∞ (0.38 to ∞)	0.238
Fresh frozen plasma
Patients	4/25 (16.0%)	4/28 (14.3%)	0.88 (0.14 to 5.34)	1
Dose, units	10 [8.5 to 12.5]	17 [10.25 to 25]	−7.5 (−30 to 15)	0.3094
Fibrinogen concentrate after admission to ED
Patients	12/25 (48.0%)	11/28 (39.3%)	0.71 (0.21 to 2.39)	0.5862
Dose (g)	4 [2 to 4.75]	4 [4 to 5.5]	−1 (−3 to 1)	0.2923
Four-factor PCCc
Patients	1/25 (4.0%)	2/28 (7.1%)	1.83 (0.09 to 113.31)	1
Tranexamic acid after admission to ED
Patients	10/25 (40.0%)	6/28 (21.4%)	0.42 (0.10 to 1.59)	0.2304
Dose (g)	1.5 [1 to 2]	2 [1.25 to 2]	0 (−1 to 1)	0.6411

Values in Placebo and FC groups are median [IQR] or number (%).

ED, emergency department; PCC, prothrombin complex concentrate.

^aAll patients received crystalloids during the first 24 h after injury.

^bMore than 9 units in 24 h.

^cThe patient in the Placebo group received 1200 units; the two patients in the FC group received 1000 units and 1200 units of four-factor PCC.